Let’s Outdo Cancer.

Bladder cancer is the 6th most common cancer in the U.S. In 2024, an estimated 80,000 new cases of bladder cancer will be diagnosed in the U.S. Men are four times more likely to be diagnosed with bladder cancer than women. Though the rates of both new bladder cancers and deaths from bladder cancer have been dropping in recent years, many people still face cancer progression and advanced bladder cancer is a common cause of cancer-related death.

Worldwide, breast cancer is the most common invasive cancer, with more than 2.2 million impacted annually. Metastatic breast cancer (mBC), the most advanced stage of breast cancer in which the cancer has spread beyond the breast to other parts of the body (i.e., organs, bones), remains an incurable disease. As a result of earlier screening, increased awareness, and better treatments, breast cancer deaths have continued to decrease in older women. From 2013 to 2018, the death rate went down by 1% per year. 

Cervical cancer begins in the cervix, which is found in the lower part of the uterus that connects to the vagina. In 2024, an estimated over 13,000 new cases of cervical cancer will be diagnosed in the U.S. Despite advances in vaccination and preventative screening practices, approximately 15% of patients present with metastatic disease at diagnosis. Among patients with initial diagnosis of early-stage disease, up to 61% will recur. Recurrent or metastatic cervical cancer is a devastating and mostly incurable disease with an urgent need for more treatment options. Patients who experience disease progression on or after first-line systemic therapy have limited effective therapy choices.

Worldwide, colorectal cancer is the third most common type of cancer in men, and the second most common in women, with approximately 1.8 million new diagnoses in 2018. In the U.S. alone, an estimated 147,950 people will be diagnosed with cancer of the colon or rectum in 2020, and approximately 53,000 are estimated to die of their disease each year. 

Head and neck cancers occur in the larynx, throat, lips, mouth, nose, and salivary glands. About 4% of all cancers in the U.S. are head and neck cancers. These cancers are more than twice as common among men than among women. In 2023, an estimated over 65,000 new cases of head and neck cancer were diagnosed in the U.S. There is a high need for additional effective treatment options for head and neck cancers.

Blood cancers strike ruthlessly at any age. Some come fast and take lives within weeks or months. Others develop in the bones and blood over time, requiring intense and aggressive treatment interventions that are traumatic, emotionally overwhelming, and expensive. More than 1 million people worldwide were diagnosed with a blood cancer in 2020, representing almost 6% of all cancer diagnoses globally. In 2020, more than 700,000 people worldwide died from a form of blood cancer. 

Lung cancer remains the leading cause of cancer-related death among men and women globally, and the global five-year survival rate at 17.8 percent is much lower than leading cancers. Lung cancer is notoriously difficult to treat due to the heterogeneous nature of the disease, variability in testing rates and the onset of drug resistance. These challenges necessitate an individualized approach to treatment, ensuring people with lung cancer receive the right drug at the right time.

Though melanoma skin cancer is much less common (1%) than some other types of skin cancers, it causes the vast majority of skin cancer deaths. It is considered more dangerous because it’s much more likely to invade nearby tissue and spread to other parts of the body if not caught and treated early when it is most likely to be cured. 

Prostate cancer is the most common cancer in men in the U.S., aside from non-melanoma skin cancer, and is a leading cause of death from cancer. About 1 in 8 men will be diagnosed with prostate cancer in their lifetimes. Black men are 70% more likely than White men to be diagnosed with prostate cancer. In 2024, an estimated 300,000 new cases of prostate cancer will be diagnosed in the U.S. Though the death rate had been improving, lately this trend has slowed. This change is likely from an increase in later-stage diagnoses that are more difficult to treat.